Arcutis Biotherapeutics, Inc. ARQT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s total current liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported total current liabilities of $163.2M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s total current liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s total current liabilities increased by 79.1% year-over-year, from $91.13M to $163.2M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s total current liabilities has grown at a 41.9% compound annual growth rate (CAGR), from $22.6M to $129.84M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.